98%
921
2 minutes
20
Cyclin-dependent kinase 20 (CDK20), also known as cell cycle-related kinase (CCRK), plays a pivotal role in hepatocellular carcinoma (HCC) progression by regulating β-catenin signaling and promoting uncontrolled proliferation. Despite its emerging significance, selective small-molecule inhibitors of CDK20 remain unexplored. In this study, a known CDK20 inhibitor, ISM042-2-048, was employed as a reference to retrieve structurally similar compounds from the PubChem database using an 85% similarity threshold. Out of 6,235 candidates, the top three compounds (153295720, 145037521, and 163292314) were shortlisted through MTiOpenScreen-based virtual screening. Geometry optimizations using density functional theory (B3LYP/cc-pVDZ) refined each ligand's electronic properties before re-docking against the AlphaFold-derived CDK20 structure. 153295720 exhibited the highest binding affinity (- 11.8 kcal/mol), engaging critical active-site residues such as Met, Lys, Ala, and Asp through polar and hydrophobic interactions. Molecular dynamics simulations (500 ns) confirmed the complex's structural stability, with 153295720 showing the lowest RMSD and RMSF fluctuations and highly persistent hydrogen bonding. MM/GBSA analysis further supported its superiority, revealing the most favorable binding energy (- 69.09 ± 8.29 kcal/mol), dominated by van der Waals and electrostatic interactions. Free energy landscape analysis revealed a single dominant basin, and superimposition of MD-derived minima with the docked pose yielded an RMSD of 1.464 Å, supporting pose fidelity. Comparatively, the reference compound displayed greater conformational drift and reduced energetic convergence. This integrative computational approach establishes 153295720 as a structurally and dynamically superior inhibitor, capable of stabilizing key catalytic residues of CDK20. These findings provide a rational basis for the biochemical targeting of CDK20 in HCC and highlight residues essential for selective inhibition, paving the way for experimental validation and lead optimization.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11030-025-11339-8 | DOI Listing |
Eur J Gastroenterol Hepatol
September 2025
Department of General Medicine, Affiliated Anqing First People's Hospital of Anhui Medical University, Anqing, Anhui, China.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-associated death globally. Second-line therapies are crucial for improving survival and quality of life among individuals suffering from advanced HCC who have not responded to first-line therapies. This study sought to evaluate the safety and efficacy of different second-line therapies for advanced HCC by network meta-analysis.
View Article and Find Full Text PDFArq Gastroenterol
September 2025
Universidade Federal da Bahia, Hospital Universitário Professor Edgard Santos, Serviço de Gastro-Hepatologia, Salvador, BA, Brasil.
Background: Since Ludwig proposed the term "nonalcoholic steatohepatitis" (NASH) for this liver disease in 1980, there have been many advances in understanding it, including its epidemiology, pathogenesis, diagnostic methods, and treatment.
Objective: This literature review aims to discuss the most relevant aspects of metabolic dysfunction-associated steatotic liver disease (MASLD).
Methods: The review included clinical studies from the following databases: Embase, PubMed, Scopus, Web of Science, Lilacs, Ovid, and Scopus.
Mol Divers
September 2025
Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, 11942, Al Kharj, Saudi Arabia.
Cyclin-dependent kinase 20 (CDK20), also known as cell cycle-related kinase (CCRK), plays a pivotal role in hepatocellular carcinoma (HCC) progression by regulating β-catenin signaling and promoting uncontrolled proliferation. Despite its emerging significance, selective small-molecule inhibitors of CDK20 remain unexplored. In this study, a known CDK20 inhibitor, ISM042-2-048, was employed as a reference to retrieve structurally similar compounds from the PubChem database using an 85% similarity threshold.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Background: Postoperative late recurrence (POLAR) after 2 years from the date of surgical resection of hepatocellular carcinoma (HCC) represents a unique surveillance and management challenge. Despite identified risk factors, individualized prediction tools to guide personalized surveillance strategies for recurrence remain scarce. The current study sought to develop a predictive model for late recurrence among patients undergoing HCC resection.
View Article and Find Full Text PDFRev Med Suisse
August 2025
Service de gastroentérologie et d'hépatologie, Département de médecine, Centre hospitalier universitaire vaudois et Université de Lausanne, 1011 Lausanne.
Viral hepatitis is associated with high morbidity and mortality worldwide. Hepatitis A and E viruses are enterally transmitted and typically cause acute self-limited hepatitis. Hepatitis B, C, and D viruses are parenterally transmitted and can cause chronic hepatitis, with potential progression to cirrhosis and hepatocellular carcinoma.
View Article and Find Full Text PDF